

Table 1.14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Both Sexes, 21 SEER Areas, 2015-2017

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	39.55	(39.48, 39.62)	39.72	(39.65, 39.80)	36.17	(35.97, 36.38)
Invasive and In Situ	42.05	(41.98, 42.13)	42.24	(42.16, 42.32)	37.58	(37.38, 37.79)
Oral Cavity and Pharynx	1.17	(1.16, 1.18)	1.23	(1.22, 1.24)	0.78	(0.75, 0.81)
Esophagus	0.50	(0.50, 0.51)	0.54	(0.53, 0.54)	0.38	(0.36, 0.40)
Stomach	0.84	(0.83, 0.85)	0.74	(0.73, 0.75)	1.08	(1.04, 1.11)
Colon and Rectum	4.15	(4.13, 4.18)	4.09	(4.07, 4.12)	4.15	(4.08, 4.22)
Invasive and In Situ	4.30	(4.28, 4.32)	4.23	(4.20, 4.25)	4.32	(4.25, 4.39)
Liver and Intrahepatic Bile Duct	1.03	(1.02, 1.04)	0.93	(0.92, 0.95)	1.10	(1.06, 1.13)
Pancreas	1.65	(1.63, 1.66)	1.64	(1.63, 1.66)	1.68	(1.64, 1.73)
Larynx	0.31	(0.31, 0.32)	0.32	(0.31, 0.32)	0.38	(0.36, 0.40)
Invasive and In Situ	0.34	(0.33, 0.34)	0.34	(0.33, 0.35)	0.40	(0.38, 0.42)
Lung and Bronchus	6.27	(6.24, 6.30)	6.45	(6.41, 6.48)	5.54	(5.46, 5.62)
Melanoma of the Skin	2.27	(2.25, 2.28)	2.66	(2.64, 2.68)	0.10	(0.08, 0.11)
Invasive and In Situ	4.00	(3.97, 4.02)	4.59	(4.56, 4.61)	0.13	(0.12, 0.15)
Breast	6.62	(6.59, 6.65)	6.67	(6.64, 6.70)	6.28	(6.20, 6.37)
Invasive and In Situ	7.82	(7.80, 7.85)	7.82	(7.79, 7.86)	7.55	(7.46, 7.63)
Urinary Bladder (Invasive and In Situ)	2.44	(2.42, 2.46)	2.65	(2.63, 2.67)	1.29	(1.25, 1.34)
Kidney and Renal Pelvis	1.70	(1.69, 1.72)	1.76	(1.75, 1.78)	1.59	(1.55, 1.63)
Brain and Other Nervous System	0.62	(0.61, 0.63)	0.68	(0.67, 0.69)	0.35	(0.33, 0.37)
Thyroid	1.28	(1.27, 1.29)	1.33	(1.32, 1.35)	0.76	(0.73, 0.78)
Hodgkin Lymphoma	0.21	(0.21, 0.22)	0.23	(0.22, 0.23)	0.19	(0.18, 0.21)
Non-Hodgkin Lymphoma	2.15	(2.13, 2.16)	2.25	(2.23, 2.27)	1.37	(1.33, 1.41)
Myeloma	0.83	(0.82, 0.84)	0.76	(0.75, 0.77)	1.44	(1.40, 1.48)
Leukemia	1.55	(1.53, 1.56)	1.63	(1.62, 1.65)	1.05	(1.02, 1.09)
Acute Lymphocytic Leukemia	0.14	(0.13, 0.14)	0.15	(0.14, 0.15)	0.07	(0.07, 0.08)
Chronic Lymphocytic Leukemia	0.60	(0.60, 0.61)	0.65	(0.64, 0.66)	0.34	(0.32, 0.37)
Acute Myeloid Leukemia	0.48	(0.47, 0.49)	0.50	(0.49, 0.51)	0.37	(0.35, 0.39)
Chronic Myeloid Leukemia	0.21	(0.20, 0.21)	0.22	(0.21, 0.22)	0.17	(0.15, 0.18)
Kaposi Sarcoma	0.11	(0.11, 0.12)	0.13	(0.12, 0.13)	0.05	(0.04, 0.06)
Mesothelioma	0.04	(0.04, 0.04)	0.03	(0.03, 0.04)	0.08	(0.07, 0.08)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.14 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Both Sexes, 21 SEER Areas, 2015-2017

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	34.39 (34.12, 34.67)	27.75 (26.78, 28.79)	36.39 (36.16, 36.63)
Invasive and In Situ	35.87 (35.60, 36.15)	28.56 (27.58, 29.61)	37.83 (37.59, 38.08)
Oral Cavity and Pharynx	0.97 (0.93, 1.02)	0.79 (0.67, 1.02)	0.80 (0.77, 0.84)
Esophagus	0.33 (0.31, 0.36)	0.46 (0.33, 0.70)	0.39 (0.36, 0.42)
Stomach	1.57 (1.51, 1.64)	0.83 (0.66, 1.10)	1.36 (1.31, 1.41)
Colon and Rectum	4.26 (4.16, 4.36)	4.16 (3.77, 4.63)	4.16 (4.08, 4.24)
Invasive and In Situ	4.40 (4.30, 4.51)	4.23 (3.85, 4.71)	4.32 (4.24, 4.41)
Liver and Intrahepatic Bile Duct	1.79 (1.73, 1.86)	1.62 (1.43, 1.90)	1.76 (1.70, 1.81)
Pancreas	1.64 (1.57, 1.70)	1.39 (1.16, 1.71)	1.70 (1.64, 1.76)
Larynx	0.15 (0.13, 0.17)	0.27 (0.19, 0.47)	0.27 (0.25, 0.29)
Invasive and In Situ	0.16 (0.14, 0.18)	0.28 (0.20, 0.49)	0.29 (0.27, 0.31)
Lung and Bronchus	5.53 (5.42, 5.66)	4.45 (4.03, 4.95)	4.03 (3.94, 4.11)
Melanoma of the Skin	0.17 (0.15, 0.19)	0.49 (0.39, 0.70)	0.55 (0.52, 0.58)
Invasive and In Situ	0.24 (0.22, 0.27)	0.80 (0.67, 1.04)	0.89 (0.85, 0.93)
Breast	5.90 (5.80, 6.00)	4.04 (3.71, 4.46)	5.55 (5.47, 5.63)
Invasive and In Situ	7.32 (7.22, 7.43)	4.62 (4.27, 5.04)	6.60 (6.51, 6.69)
Urinary Bladder (Invasive and In Situ)	1.47 (1.41, 1.54)	1.24 (1.05, 1.53)	1.59 (1.53, 1.65)
Kidney and Renal Pelvis	1.12 (1.08, 1.17)	1.81 (1.61, 2.09)	1.86 (1.81, 1.91)
Brain and Other Nervous System	0.41 (0.38, 0.44)	0.37 (0.25, 0.61)	0.55 (0.52, 0.58)
Thyroid	1.40 (1.36, 1.44)	0.81 (0.67, 1.06)	1.26 (1.22, 1.29)
Hodgkin Lymphoma	0.11 (0.10, 0.13)	0.11 (0.07, 0.30)	0.21 (0.19, 0.22)
Non-Hodgkin Lymphoma	1.81 (1.74, 1.87)	1.19 (0.99, 1.48)	2.24 (2.18, 2.30)
Myeloma	0.56 (0.53, 0.60)	0.67 (0.51, 0.93)	0.88 (0.84, 0.91)
Leukemia	1.01 (0.96, 1.06)	0.79 (0.66, 1.03)	1.24 (1.19, 1.28)
Acute Lymphocytic Leukemia	0.12 (0.11, 0.14)	0.13 (0.10, 0.31)	0.21 (0.19, 0.22)
Chronic Lymphocytic Leukemia	0.18 (0.16, 0.20)	0.21 (0.14, 0.40)	0.30 (0.28, 0.33)
Acute Myeloid Leukemia	0.46 (0.43, 0.50)	0.20 (0.14, 0.39)	0.44 (0.41, 0.47)
Chronic Myeloid Leukemia	0.16 (0.14, 0.19)	0.14 (0.08, 0.33)	0.18 (0.16, 0.20)
Kaposi Sarcoma	0.06 (0.04, 0.07)	0.08 (0.03, 0.28)	0.10 (0.08, 0.11)
Mesothelioma	0.02 (0.01, 0.03)	0.05 (0.02, 0.25)	0.07 (0.06, 0.09)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Males, 21 SEER Areas, 2015-2017

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	40.46	(40.36, 40.57)	40.15	(40.04, 40.27)	38.04	(37.74, 38.36)
Invasive and In Situ	42.14	(42.04, 42.25)	41.87	(41.75, 41.99)	38.45	(38.14, 38.77)
Oral Cavity and Pharynx	1.66	(1.64, 1.68)	1.74	(1.72, 1.77)	1.11	(1.06, 1.16)
Esophagus	0.79	(0.78, 0.81)	0.85	(0.83, 0.86)	0.55	(0.51, 0.59)
Stomach	1.04	(1.02, 1.06)	0.93	(0.91, 0.95)	1.27	(1.21, 1.34)
Colon and Rectum	4.30	(4.27, 4.33)	4.21	(4.18, 4.25)	4.33	(4.23, 4.44)
Invasive and In Situ	4.46	(4.43, 4.50)	4.36	(4.33, 4.40)	4.51	(4.40, 4.62)
Liver and Intrahepatic Bile Duct	1.46	(1.44, 1.47)	1.31	(1.29, 1.33)	1.64	(1.59, 1.70)
Pancreas	1.68	(1.66, 1.70)	1.69	(1.66, 1.71)	1.59	(1.53, 1.66)
Larynx	0.52	(0.50, 0.53)	0.52	(0.50, 0.53)	0.64	(0.60, 0.68)
Invasive and In Situ	0.55	(0.54, 0.57)	0.56	(0.54, 0.57)	0.67	(0.63, 0.71)
Lung and Bronchus	6.57	(6.52, 6.61)	6.58	(6.54, 6.63)	6.34	(6.21, 6.47)
Melanoma of the Skin	2.79	(2.76, 2.81)	3.23	(3.20, 3.26)	0.10	(0.08, 0.12)
Invasive and In Situ	4.84	(4.80, 4.88)	5.49	(5.45, 5.54)	0.13	(0.11, 0.15)
Breast	0.13	(0.13, 0.14)	0.13	(0.13, 0.14)	0.17	(0.15, 0.19)
Invasive and In Situ	0.15	(0.14, 0.15)	0.14	(0.14, 0.15)	0.18	(0.16, 0.21)
Prostate	12.12	(12.06, 12.17)	11.28	(11.22, 11.34)	16.29	(16.10, 16.49)
Testis	0.41	(0.40, 0.41)	0.48	(0.47, 0.49)	0.11	(0.10, 0.13)
Urinary Bladder (Invasive and In Situ)	3.85	(3.81, 3.88)	4.16	(4.12, 4.20)	1.84	(1.76, 1.92)
Kidney and Renal Pelvis	2.18	(2.15, 2.20)	2.24	(2.22, 2.27)	1.98	(1.92, 2.05)
Brain and Other Nervous System	0.69	(0.68, 0.70)	0.76	(0.74, 0.77)	0.38	(0.35, 0.41)
Thyroid	0.69	(0.67, 0.70)	0.73	(0.72, 0.74)	0.32	(0.29, 0.35)
Hodgkin Lymphoma	0.23	(0.22, 0.24)	0.24	(0.24, 0.25)	0.21	(0.19, 0.23)
Non-Hodgkin Lymphoma	2.40	(2.38, 2.43)	2.51	(2.48, 2.54)	1.47	(1.42, 1.54)
Myeloma	0.95	(0.94, 0.97)	0.89	(0.87, 0.91)	1.50	(1.44, 1.57)
Leukemia	1.83	(1.81, 1.86)	1.93	(1.91, 1.96)	1.18	(1.12, 1.24)
Acute Lymphocytic Leukemia	0.15	(0.14, 0.16)	0.16	(0.16, 0.17)	0.08	(0.07, 0.10)
Chronic Lymphocytic Leukemia	0.74	(0.73, 0.75)	0.79	(0.77, 0.81)	0.42	(0.39, 0.46)
Acute Myeloid Leukemia	0.56	(0.54, 0.57)	0.58	(0.56, 0.59)	0.38	(0.35, 0.42)
Chronic Myeloid Leukemia	0.25	(0.24, 0.26)	0.26	(0.25, 0.27)	0.19	(0.17, 0.22)
Kaposi Sarcoma	0.18	(0.17, 0.19)	0.20	(0.19, 0.21)	0.09	(0.07, 0.11)
Mesothelioma	0.07	(0.07, 0.08)	0.06	(0.05, 0.06)	0.14	(0.13, 0.16)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Males, 21 SEER Areas, 2015-2017

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	34.92 (34.50, 35.34)	26.69 (25.37, 28.21)	37.16 (36.79, 37.54)
Invasive and In Situ	35.23 (34.81, 35.66)	26.96 (25.64, 28.49)	37.71 (37.34, 38.09)
Oral Cavity and Pharynx	1.29 (1.22, 1.36)	1.13 (0.92, 1.64)	1.10 (1.04, 1.17)
Esophagus	0.53 (0.48, 0.59)	0.59 (0.44, 1.08)	0.64 (0.59, 0.71)
Stomach	1.89 (1.79, 1.99)	0.96 (0.74, 1.48)	1.57 (1.50, 1.66)
Colon and Rectum	4.61 (4.46, 4.76)	3.78 (3.28, 4.53)	4.53 (4.41, 4.67)
Invasive and In Situ	4.78 (4.63, 4.94)	3.90 (3.39, 4.66)	4.72 (4.59, 4.85)
Liver and Intrahepatic Bile Duct	2.54 (2.44, 2.65)	2.28 (1.96, 2.86)	2.36 (2.28, 2.45)
Pancreas	1.64 (1.55, 1.75)	1.70 (1.30, 2.38)	1.65 (1.57, 1.74)
Larynx	0.28 (0.24, 0.33)	0.40 (0.27, 0.89)	0.48 (0.44, 0.53)
Invasive and In Situ	0.29 (0.26, 0.34)	0.43 (0.29, 0.93)	0.52 (0.48, 0.58)
Lung and Bronchus	6.71 (6.51, 6.91)	4.33 (3.73, 5.18)	4.49 (4.35, 4.63)
Melanoma of the Skin	0.20 (0.16, 0.24)	0.53 (0.37, 1.03)	0.55 (0.51, 0.60)
Invasive and In Situ	0.28 (0.24, 0.33)	0.86 (0.66, 1.38)	0.87 (0.82, 0.94)
Breast	0.09 (0.07, 0.12)	0.03 (0.00, 0.54)	0.09 (0.07, 0.11)
Invasive and In Situ	0.10 (0.08, 0.13)	0.04 (0.01, 0.55)	0.09 (0.07, 0.12)
Prostate	7.94 (7.75, 8.13)	5.62 (5.03, 6.44)	11.03 (10.84, 11.22)
Testis	0.16 (0.15, 0.19)	0.30 (0.23, 0.76)	0.39 (0.37, 0.41)
Urinary Bladder (Invasive and In Situ)	2.42 (2.30, 2.56)	1.84 (1.51, 2.45)	2.56 (2.45, 2.68)
Kidney and Renal Pelvis	1.50 (1.43, 1.59)	2.09 (1.80, 2.66)	2.34 (2.26, 2.43)
Brain and Other Nervous System	0.46 (0.42, 0.51)	0.41 (0.28, 0.90)	0.59 (0.55, 0.64)
Thyroid	0.74 (0.70, 0.79)	0.31 (0.21, 0.78)	0.57 (0.53, 0.61)
Hodgkin Lymphoma	0.13 (0.11, 0.16)	0.09 (0.04, 0.58)	0.22 (0.20, 0.25)
Non-Hodgkin Lymphoma	2.15 (2.04, 2.26)	1.05 (0.83, 1.58)	2.39 (2.30, 2.49)
Myeloma	0.68 (0.62, 0.74)	0.74 (0.55, 1.26)	0.97 (0.92, 1.04)
Leukemia	1.21 (1.13, 1.29)	1.04 (0.81, 1.57)	1.40 (1.34, 1.48)
Acute Lymphocytic Leukemia	0.13 (0.11, 0.17)	0.14 (0.09, 0.61)	0.22 (0.21, 0.25)
Chronic Lymphocytic Leukemia	0.23 (0.20, 0.27)	0.31 (0.20, 0.79)	0.35 (0.32, 0.40)
Acute Myeloid Leukemia	0.55 (0.50, 0.61)	0.26 (0.17, 0.74)	0.48 (0.45, 0.53)
Chronic Myeloid Leukemia	0.20 (0.17, 0.24)	0.18 (0.09, 0.67)	0.20 (0.17, 0.24)
Kaposi Sarcoma	0.09 (0.07, 0.12)	0.10 (0.03, 0.60)	0.16 (0.13, 0.19)
Mesothelioma	0.04 (0.02, 0.06)	0.06 (0.02, 0.56)	0.12 (0.10, 0.15)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 21 SEER Areas, 2015-2017

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	38.88	(38.78, 38.98)	39.54	(39.43, 39.65)	34.66	(34.39, 34.94)
Invasive and In Situ	42.22	(42.12, 42.32)	42.88	(42.77, 42.99)	36.97	(36.69, 37.25)
Oral Cavity and Pharynx	0.71	(0.70, 0.72)	0.73	(0.72, 0.75)	0.49	(0.46, 0.52)
Esophagus	0.23	(0.23, 0.24)	0.24	(0.23, 0.25)	0.24	(0.22, 0.27)
Stomach	0.66	(0.65, 0.68)	0.56	(0.55, 0.58)	0.92	(0.87, 0.97)
Colon and Rectum	4.02	(3.99, 4.05)	3.98	(3.94, 4.01)	4.00	(3.91, 4.10)
Invasive and In Situ	4.15	(4.11, 4.18)	4.10	(4.06, 4.13)	4.16	(4.06, 4.26)
Liver and Intrahepatic Bile Duct	0.62	(0.61, 0.63)	0.57	(0.55, 0.58)	0.61	(0.58, 0.65)
Pancreas	1.62	(1.60, 1.64)	1.60	(1.58, 1.62)	1.76	(1.70, 1.83)
Larynx	0.12	(0.12, 0.13)	0.13	(0.12, 0.13)	0.16	(0.14, 0.18)
Invasive and In Situ	0.13	(0.13, 0.14)	0.14	(0.13, 0.14)	0.17	(0.15, 0.19)
Lung and Bronchus	6.04	(6.00, 6.08)	6.36	(6.31, 6.40)	4.89	(4.78, 4.99)
Melanoma of the Skin	1.80	(1.79, 1.83)	2.14	(2.12, 2.17)	0.10	(0.08, 0.11)
Invasive and In Situ	3.25	(3.22, 3.27)	3.77	(3.74, 3.80)	0.14	(0.12, 0.16)
Breast	12.86	(12.81, 12.92)	13.13	(13.07, 13.19)	11.65	(11.50, 11.80)
Invasive and In Situ	15.23	(15.18, 15.29)	15.43	(15.36, 15.49)	14.02	(13.86, 14.18)
Cervix Uteri	0.63	(0.62, 0.64)	0.61	(0.60, 0.62)	0.76	(0.72, 0.79)
Corpus and Uterus, NOS	3.11	(3.09, 3.14)	3.15	(3.13, 3.18)	3.07	(2.99, 3.14)
Invasive and In Situ	3.13	(3.10, 3.16)	3.17	(3.14, 3.20)	3.09	(3.02, 3.17)
Ovary ^a	1.22	(1.21, 1.24)	1.27	(1.25, 1.29)	0.95	(0.90, 0.99)
Urinary Bladder (Invasive and In Situ)	1.17	(1.15, 1.18)	1.25	(1.23, 1.27)	0.85	(0.80, 0.90)
Kidney and Renal Pelvis	1.26	(1.24, 1.27)	1.29	(1.27, 1.31)	1.25	(1.20, 1.30)
Brain and Other Nervous System	0.55	(0.54, 0.56)	0.61	(0.60, 0.62)	0.32	(0.29, 0.35)
Thyroid	1.88	(1.86, 1.90)	1.96	(1.94, 1.98)	1.16	(1.12, 1.20)
Hodgkin Lymphoma	0.19	(0.19, 0.20)	0.21	(0.20, 0.21)	0.18	(0.17, 0.20)
Non-Hodgkin Lymphoma	1.91	(1.89, 1.94)	2.01	(1.98, 2.03)	1.28	(1.23, 1.33)
Myeloma	0.72	(0.71, 0.73)	0.64	(0.62, 0.65)	1.40	(1.34, 1.45)
Leukemia	1.29	(1.27, 1.31)	1.35	(1.33, 1.37)	0.96	(0.91, 1.00)
Acute Lymphocytic Leukemia	0.12	(0.12, 0.13)	0.13	(0.12, 0.14)	0.07	(0.06, 0.08)
Chronic Lymphocytic Leukemia	0.48	(0.47, 0.49)	0.52	(0.51, 0.54)	0.28	(0.26, 0.31)
Acute Myeloid Leukemia	0.42	(0.41, 0.43)	0.43	(0.42, 0.44)	0.36	(0.33, 0.39)
Chronic Myeloid Leukemia	0.17	(0.17, 0.18)	0.18	(0.17, 0.18)	0.15	(0.13, 0.17)
Kaposi Sarcoma	0.05	(0.05, 0.06)	0.06	(0.06, 0.07)	0.02	(0.02, 0.03)
Mesothelioma	0.01	(0.01, 0.01)	0.01	(0.01, 0.01)	0.02	(0.01, 0.02)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Females, 21 SEER Areas, 2015-2017

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	34.13 (33.77, 34.49)	28.91 (27.52, 30.44)	36.26 (35.95, 36.58)
Invasive and In Situ	36.63 (36.26, 37.00)	30.25 (28.84, 31.81)	38.56 (38.24, 38.88)
Oral Cavity and Pharynx	0.70 (0.65, 0.76)	0.47 (0.34, 0.82)	0.54 (0.50, 0.59)
Esophagus	0.17 (0.14, 0.20)	0.32 (0.14, 0.74)	0.18 (0.15, 0.21)
Stomach	1.30 (1.22, 1.39)	0.70 (0.46, 1.14)	1.17 (1.11, 1.24)
Colon and Rectum	3.96 (3.83, 4.10)	4.52 (3.96, 5.24)	3.85 (3.74, 3.97)
Invasive and In Situ	4.08 (3.94, 4.22)	4.55 (3.99, 5.28)	4.01 (3.90, 4.12)
Liver and Intrahepatic Bile Duct	1.15 (1.08, 1.23)	1.00 (0.79, 1.39)	1.21 (1.14, 1.27)
Pancreas	1.63 (1.55, 1.73)	1.12 (0.86, 1.57)	1.75 (1.67, 1.83)
Larynx	0.04 (0.03, 0.07)	0.14 (0.06, 0.49)	0.08 (0.07, 0.10)
Invasive and In Situ	0.05 (0.03, 0.07)	0.14 (0.06, 0.49)	0.09 (0.07, 0.11)
Lung and Bronchus	4.57 (4.43, 4.72)	4.60 (4.02, 5.35)	3.68 (3.57, 3.80)
Melanoma of the Skin	0.15 (0.12, 0.18)	0.46 (0.34, 0.80)	0.56 (0.52, 0.60)
Invasive and In Situ	0.21 (0.18, 0.24)	0.75 (0.58, 1.13)	0.92 (0.87, 0.97)
Breast	10.95 (10.77, 11.13)	7.92 (7.29, 8.70)	10.61 (10.46, 10.76)
Invasive and In Situ	13.62 (13.43, 13.81)	9.06 (8.40, 9.87)	12.65 (12.49, 12.82)
Cervix Uteri	0.64 (0.60, 0.69)	0.62 (0.49, 0.96)	0.87 (0.83, 0.91)
Corpus and Uterus, NOS	2.48 (2.40, 2.57)	1.96 (1.70, 2.39)	2.86 (2.78, 2.94)
Invasive and In Situ	2.49 (2.41, 2.57)	1.96 (1.70, 2.39)	2.88 (2.80, 2.96)
Ovary ^c	1.06 (1.01, 1.12)	0.83 (0.66, 1.21)	1.24 (1.19, 1.30)
Urinary Bladder (Invasive and In Situ)	0.68 (0.63, 0.75)	0.69 (0.49, 1.09)	0.80 (0.74, 0.86)
Kidney and Renal Pelvis	0.79 (0.74, 0.85)	1.53 (1.28, 1.97)	1.44 (1.38, 1.50)
Brain and Other Nervous System	0.36 (0.33, 0.40)	0.32 (0.15, 0.73)	0.51 (0.47, 0.55)
Thyroid	2.00 (1.93, 2.06)	1.31 (1.05, 1.75)	1.95 (1.90, 2.01)
Hodgkin Lymphoma	0.10 (0.09, 0.12)	0.14 (0.07, 0.47)	0.19 (0.18, 0.22)
Non-Hodgkin Lymphoma	1.53 (1.45, 1.61)	1.31 (1.01, 1.79)	2.12 (2.04, 2.20)
Myeloma	0.46 (0.42, 0.51)	0.59 (0.37, 1.02)	0.80 (0.75, 0.85)
Leukemia	0.84 (0.78, 0.91)	0.56 (0.42, 0.92)	1.10 (1.04, 1.16)
Acute Lymphocytic Leukemia	0.11 (0.10, 0.14)	0.13 (0.08, 0.45)	0.19 (0.17, 0.21)
Chronic Lymphocytic Leukemia	0.14 (0.11, 0.17)	0.11 (0.04, 0.45)	0.26 (0.23, 0.29)
Acute Myeloid Leukemia	0.39 (0.35, 0.43)	0.14 (0.07, 0.48)	0.40 (0.37, 0.44)
Chronic Myeloid Leukemia	0.13 (0.11, 0.16)	0.11 (0.05, 0.44)	0.16 (0.14, 0.19)
Kaposi Sarcoma	0.03 (0.02, 0.05)	0.07 (0.01, 0.41)	0.05 (0.04, 0.06)
Mesothelioma	0.01 (0.00, 0.02)	0.04 (0.00, 0.38)	0.03 (0.02, 0.04)

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the PRCA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.